Resource Summary Report

Generated by RRID on Sep 8, 2026

PE/Cyanine7 anti-human/mouse Granzyme B Recombinant

RRID:AB_2801079
Type: Antibody

Proper Citation

BioLegend Cat# 396410, RRID:AB_2801079

Antibody Information

URL: http://antibodyregistry.org/AB_2801079

Proper Citation: BioLegend Cat# 396410, RRID:AB_2801079

Target Antigen: Granzyme B

Host Organism: rat

Clonality: recombinant monoclonal

Comments: Applications: ICFC

Antibody Name: PE/Cyanine7 anti-human/mouse Granzyme B Recombinant

Description: This recombinant monoclonal targets Granzyme B

Target Organism: Human, Mouse

Clone ID: Clone QA18A28

Antibody ID: AB_2801079

Vendor: BioLegend

Catalog Number: 396410

Alternative Catalog Numbers: 396409

Record Creation Time: 20231110T032753+0000

Record Last Update: 20260829T104033+0000

Ratings and Alerts

No rating or validation information has been found for PE/Cyanine7 anti-human/mouse Granzyme B Recombinant.

No alerts have been found for PE/Cyanine7 anti-human/mouse Granzyme B Recombinant.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Jakobsen JS, et al. (2026) Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti-PD-1 Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(6), 1120.

Hu Z, et al. (2026) Extracellular ATP-P2RY2 signaling drives intratumoral prostaglandin E2 accumulation and adaptive resistance to immunotherapy in solid tumors. Immunity, 59(7), 1928.

Wang CY, et al. (2024) UB-612 pan-SARS-CoV-2 T cell immunity-promoting vaccine protects against COVID-19 moderate-severe disease. iScience, 27(2), 108887.

Lin F, et al. (2024) Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment. Cell, 187(26), 7470.

Luoma AM, et al. (2022) Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy. Cell, 185(16), 2918.

Chen W, et al. (2022) Chronic type I interferon signaling promotes lipid-peroxidation-driven terminal CD8+ T cell exhaustion and curtails anti-PD-1 efficacy. Cell reports, 41(7), 111647.